Loading
A phase 1/2 trial of FAP-2286 (177Lu / 68Ga) in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04939610 by Novartis Pharmaceuticals, with 222 participants planned, started 2021-07-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: 68Ga-FAP-2286 and 177Lu-FAP-2286.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/